Fundraising FoxQ Therapeutics
Salt Lake City, US · 6 known investors
Find your way into Q Therapeutics
Sign up to see every warm intro you have to Q Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Q Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Q Therapeutics develops allogeneic, human glial progenitor cell therapies for currently incurable diseases of the central nervous system. Its lead candidate, Q-Cells, is an off-the-shelf cell therapy that replaces myelin and supports neuron repair, with FDA allowance to begin a Phase 1/2a trial in Transverse Myelitis patients.
Investors · 6
Also in the syndicate · 4
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BFeb 2008
vSpring Capital (lead), Epic Ventures (Formerly Wasatch Venture Fund), Invitrogen Corporation, Toucan Capital, University of Utah Research Foundation
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Q Therapeutics do?
- Q Therapeutics develops allogeneic, human glial progenitor cell therapies for currently incurable diseases of the central nervous system. Its lead candidate, Q-Cells, is an off-the-shelf cell therapy that replaces myelin and supports neuron repair, with FDA allowance to begin a Phase 1/2a trial in Transverse Myelitis patients.
- Who are Q Therapeutics's investors?
- Q Therapeutics's investors include EPIC VENTURES, UpStart Ventures.
- Where is Q Therapeutics headquartered?
- Q Therapeutics is headquartered in Salt Lake City, US.